Skip to content

Moderna, Inc.

MRNA · XNAS

CIK 1682852fmd_0XPRKE5NEEA60RYHKPK4BHE9HJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods

Latest annual · FY2025

Millions
Total revenues
1,944
Gross profit
1,076
Operating income
(3,074)
Net income
(2,822)
Free cash flow
(2,065)

Latest quarter · Q3 FY2026

Millions
Total revenues
1,313
Gross profit
995
Operating income
130
Net income
162
Free cash flow
(1,606)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
-53.4%
Revenue, 5 yearsFY2020 to FY2025
+19.3%
Net income, 5 yearsFY2020 to FY2025
n/m

Moderna, Inc. (MRNA) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$1.9 billion$3.2 billion-39.9%10-K 2026-02-20 · proof
Gross profit$1.1 billion$1.8 billion-39.3%10-K 2026-02-20 · proof
Operating income-$3.1 billion-$3.9 billion10-K 2026-02-20 · proof
Net income-$2.8 billion-$3.6 billion10-K 2026-02-20 · proof
Cash from operating activities-$1.9 billion-$3 billion10-K 2026-02-20 · proof
Free cash flow-$2.1 billion-$4.1 billion10-K 2026-02-20 · proof
Total assets$12.3 billion$14.1 billion-12.8%10-K 2026-02-20 · proof
Total liabilities$3.7 billion$3.2 billion+13.8%10-K 2026-02-20 · proof
Cash and cash equivalents$2.6 billion$1.9 billion+34.7%10-K 2026-02-20 · proof
What was Moderna, Inc. (MRNA)'s revenue in fiscal 2025?
Moderna, Inc. (MRNA) reported revenue of $1.9 billion for fiscal 2025 (the year ended Dec 31, 2025), against $3.2 billion the year before (-39.9%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was Moderna, Inc. (MRNA)'s gross profit in fiscal 2025?
Moderna, Inc. (MRNA) reported gross profit of $1.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.8 billion the year before (-39.3%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was Moderna, Inc. (MRNA)'s operating income in fiscal 2025?
Moderna, Inc. (MRNA) reported operating income of -$3.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against -$3.9 billion the year before. Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was Moderna, Inc. (MRNA)'s net income in fiscal 2025?
Moderna, Inc. (MRNA) reported net income of -$2.8 billion for fiscal 2025 (the year ended Dec 31, 2025), against -$3.6 billion the year before. Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was Moderna, Inc. (MRNA)'s cash from operating activities in fiscal 2025?
Moderna, Inc. (MRNA) reported cash from operating activities of -$1.9 billion for fiscal 2025 (the year ended Dec 31, 2025), against -$3 billion the year before. Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was Moderna, Inc. (MRNA)'s free cash flow in fiscal 2025?
Moderna, Inc. (MRNA) reported free cash flow of -$2.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against -$4.1 billion the year before. Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What are Moderna, Inc. (MRNA)'s total assets?
As of Dec 31, 2025, Moderna, Inc. (MRNA) reported total assets of $12.3 billion, against $14.1 billion a year earlier (-12.8%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What are Moderna, Inc. (MRNA)'s total liabilities?
As of Dec 31, 2025, Moderna, Inc. (MRNA) reported total liabilities of $3.7 billion, against $3.2 billion a year earlier (+13.8%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What are Moderna, Inc. (MRNA)'s cash and cash equivalents?
As of Dec 31, 2025, Moderna, Inc. (MRNA) reported cash and cash equivalents of $2.6 billion, against $1.9 billion a year earlier (+34.7%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:MRNA&period_type=annual&limit=5"

Information only, not investment advice.